Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

SciFest, Ireland’s largest and most inclusive STEM fair programme for second-level students, has announced its return ahead ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

MK-0616 has been shown to reduce LDL cholesterol by a similar margin to injectables sold by Amgen and Sanofi/Regeneron – as ... baseline when it was added to background therapy with statins.

Background, Key Findings Del Priore and colleagues ... Rosen disclosed relationships with Boehringer Ingelheim, Alcon Vision, Regeneron, and AbbVie. Source Reference: Shen LL, et al "Determinants ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...